Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹47.85, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 30x in the Biotechs industry in Asia. Total loss to shareholders of 57% over the past three years. Buy Or Sell Opportunity • Jun 09
Now 28% overvalued Over the last 90 days, the stock has fallen 9.5% to ₹45.25. The fair value is estimated to be ₹35.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has grown by 30%. Reported Earnings • Jun 03
Full year 2026 earnings released: EPS: ₹21.98 (vs ₹31.57 in FY 2025) Full year 2026 results: EPS: ₹21.98 (down from ₹31.57 in FY 2025). Revenue: ₹1.97b (down 17% from FY 2025). Net income: ₹176.1m (down 30% from FY 2025). Profit margin: 9.0% (down from 11% in FY 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. New Risk • Jun 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (57% accrual ratio). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Market cap is less than US$10m (₹389.7m market cap, or US$4.10m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Paying a dividend despite having no free cash flows. Anuncio • May 27
Nirman Agri Genetics Limited to Report Q4, 2026 Results on May 30, 2026 Nirman Agri Genetics Limited announced that they will report Q4, 2026 results on May 30, 2026 Buy Or Sell Opportunity • Apr 02
Now 21% overvalued Over the last 90 days, the stock has fallen 31% to ₹42.60. The fair value is estimated to be ₹35.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last year. Earnings per share has grown by 38%. Valuation Update With 7 Day Price Move • Dec 04
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₹71.05, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 91x in the Biotechs industry in India. Total loss to shareholders of 82% over the past year. Reported Earnings • Nov 20
First half 2026 earnings released: EPS: ₹18.20 (vs ₹16.46 in 1H 2025) First half 2026 results: EPS: ₹18.20 (up from ₹16.46 in 1H 2025). Revenue: ₹1.46b (up 30% from 1H 2025). Net income: ₹145.8m (up 27% from 1H 2025). Profit margin: 10.0% (in line with 1H 2025). Anuncio • Nov 14
Nirman Agri Genetics Limited to Report First Half, 2026 Results on Nov 14, 2025 Nirman Agri Genetics Limited announced that they will report first half, 2026 results on Nov 14, 2025 Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹95.05, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 104x in the Biotechs industry in India. Total loss to shareholders of 72% over the past year. New Risk • Oct 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹843.4m (US$9.56m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). High level of non-cash earnings (97% accrual ratio). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Market cap is less than US$10m (₹843.4m market cap, or US$9.56m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (11% net profit margin). Board Change • Oct 11
High number of new directors Non-Executive Director Sagar Chavan was the last director to join the board, commencing their role in 2025. Valuation Update With 7 Day Price Move • Oct 02
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₹170, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 61x in the Biotechs industry in India. Total loss to shareholders of 50% over the past year. New Risk • Sep 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.2% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.12b market cap, or US$12.6m). Buy Or Sell Opportunity • Sep 18
Now 20% overvalued Over the last 90 days, the stock has fallen 1.5% to ₹200. The fair value is estimated to be ₹166, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹164, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 63x in the Biotechs industry in India. Total loss to shareholders of 61% over the past year. Anuncio • Sep 10
Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2025 Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2025, at 13:00 Indian Standard Time. New Risk • Aug 24
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹872.7m market cap, or US$10.00m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). New Risk • Aug 04
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹873.9m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹873.9m market cap, or US$9.97m). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹148, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 55x in the Biotechs industry in India. Total loss to shareholders of 60% over the past year. New Risk • Jul 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.05b market cap, or US$12.2m). Buy Or Sell Opportunity • Jun 23
Now 21% overvalued Over the last 90 days, the stock has fallen 7.7% to ₹205. The fair value is estimated to be ₹169, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%. Valuation Update With 7 Day Price Move • Jun 10
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₹204, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 9.9% over the past year. Board Change • May 14
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹260, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 48x in the Biotechs industry in India. Total returns to shareholders of 35% over the past year. New Risk • Apr 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.7% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.36b market cap, or US$15.9m). Valuation Update With 7 Day Price Move • Mar 25
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹222, the stock trades at a trailing P/E ratio of 6.1x. Average trailing P/E is 52x in the Biotechs industry in India. Total returns to shareholders of 28% over the past year. Buy Or Sell Opportunity • Mar 24
Now 21% overvalued Over the last 90 days, the stock has fallen 46% to ₹211. The fair value is estimated to be ₹175, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 65% over the last 3 years. Earnings per share has grown by 40%. Valuation Update With 7 Day Price Move • Mar 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹227, the stock trades at a trailing P/E ratio of 6.3x. Average trailing P/E is 47x in the Biotechs industry in India. Total returns to shareholders of 11% over the past year. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to ₹263, the stock trades at a trailing P/E ratio of 7.3x. Average trailing P/E is 54x in the Biotechs industry in India. Total returns to shareholders of 1.2% over the past year. New Risk • Feb 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹1.72b market cap, or US$19.8m). New Risk • Feb 06
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 11% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹2.13b market cap, or US$24.3m). Reported Earnings • Feb 06
Third quarter 2025 earnings released: EPS: ₹8.40 (vs ₹5.60 in 3Q 2024) Third quarter 2025 results: EPS: ₹8.40 (up from ₹5.60 in 3Q 2024). Revenue: ₹610.7m (up 199% from 3Q 2024). Net income: ₹67.3m (up 101% from 3Q 2024). Profit margin: 11% (down from 16% in 3Q 2024). The decrease in margin was driven by higher expenses. Board Change • Jan 02
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 19
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 15
Second quarter 2025 earnings released: EPS: ₹8.01 (vs ₹5.60 in 2Q 2024) Second quarter 2025 results: EPS: ₹8.01 (up from ₹5.60 in 2Q 2024). Revenue: ₹620.9m (up 204% from 2Q 2024). Net income: ₹64.2m (up 92% from 2Q 2024). Profit margin: 10% (down from 16% in 2Q 2024). The decrease in margin was driven by higher expenses. Anuncio • Sep 27
Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2024 Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2024, at 12:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Sep 20
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹346, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 36x in the Biotechs industry in India. Total returns to shareholders of 99% over the past year. Reported Earnings • Aug 15
First quarter 2025 earnings released First quarter 2025 results: EPS: ₹8.45. Net income: ₹50.4m (up ₹50.4m from 1Q 2024). Valuation Update With 7 Day Price Move • Aug 14
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹439, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 29x in the Biotechs industry in India. Total returns to shareholders of 219% over the past year. Valuation Update With 7 Day Price Move • Jul 19
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹439, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 124% over the past year. Valuation Update With 7 Day Price Move • Jul 01
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹249, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 87% over the past year. New Risk • Jun 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.6% average weekly change). Minor Risk Market cap is less than US$100m (₹1.10b market cap, or US$13.2m). Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹185, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 70% over the past year. Anuncio • Jun 01
Nirman Agri Genetics Limited to Report Second Half, 2024 Results on May 30, 2024 Nirman Agri Genetics Limited announced that they will report second half, 2024 results on May 30, 2024 Reported Earnings • May 29
Full year 2024 earnings released: EPS: ₹17.46 (vs ₹6.72 in FY 2023) Full year 2024 results: EPS: ₹17.46 (up from ₹6.72 in FY 2023). Revenue: ₹633.4m (up 121% from FY 2023). Net income: ₹104.0m (up 160% from FY 2023). Profit margin: 16% (up from 14% in FY 2023). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Apr 22
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹223, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 35x in the Biotechs industry in India. Total returns to shareholders of 204% over the past year. Anuncio • Apr 19
Nirman Agri Genetics Limited Receives License from Department of Agriculture, Government of Telangana Nirman Agri Genetics Limited informed to the Stakeholders that the Company has been granted with License from the Government of Telangana to carry on the business of a dealer in seeds for various purposes in the State of Telangana. It will help in expanding and tapping new geographical markets. This license will magnificently support to increase revenues. Name of the regulatory or licensing authority: Department of Agriculture, Government of Telangana. Brief details of the approval/license: The Company has been granted license to sell, export, import and store the Agriculture Seeds for the various purposes in the State of Telangana. Access to this License will help in dealing of Paddy seeds in the State of Telangana. Period for which such license is valid: 5 years (From February 26, 2024 to February 24, 2029). Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹178, the stock trades at a trailing P/E ratio of 26.5x. Average trailing P/E is 32x in the Biotechs industry in India. Total returns to shareholders of 85% over the past year. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹190, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 33x in the Biotechs industry in India. Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹258, the stock trades at a trailing P/E ratio of 38.4x. Average trailing P/E is 53x in the Biotechs industry in India. Valuation Update With 7 Day Price Move • Oct 12
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹214, the stock trades at a trailing P/E ratio of 31.8x. Average trailing P/E is 32x in the Biotechs industry in India. Anuncio • Sep 13
Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2023 Nirman Agri Genetics Limited, Annual General Meeting, Sep 30, 2023, at 12:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2023 and the Reports of the Board of Directors and Auditors thereon; to Re-appoint Mr. Avinash Bhimrao Bagal, Non-Executive Non-Independent Director, who retires by rotation and being eligible, offers himself for re-appointment; to Approve the Appointment of M/s. Devendra C Belan & Associates, Chartered Accountants (ICAI Firm Registration Number: 126495W) as the Statutory Auditor of the Company for a period of 5 years; i.e. from the conclusion of this Annual General Meeting till the conclusion of Next Annual General Meeting from this Annual General Meeting; and to discuss other matters. Valuation Update With 7 Day Price Move • Aug 24
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹178, the stock trades at a trailing P/E ratio of 26.5x. Average trailing P/E is 35x in the Biotechs industry in India. New Risk • Aug 09
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹815.4m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). High level of non-cash earnings (28% accrual ratio). Market cap is less than US$10m (₹815.4m market cap, or US$9.85m). Minor Risk Revenue is less than US$5m (₹286m revenue, or US$3.5m). Valuation Update With 7 Day Price Move • Aug 07
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹161, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 37x in the Biotechs industry in Asia. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹147, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 38x in the Biotechs industry in Asia. Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹96.90, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 39x in the Biotechs industry in Asia. Valuation Update With 7 Day Price Move • Apr 27
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to ₹76.75, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 17x in the Biotechs industry in India. Valuation Update With 7 Day Price Move • Apr 12
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹67.70, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 17x in the Biotechs industry in India. Board Change • Mar 31
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. MD & Director Pranav Bagal is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.